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ABSTRACT 
Hyaluronan (HA) is a unique glycosaminoglycan present in the extracellular matrix of many 
vertebrates. HA is synthesized by a group of enzymes found in the plasma membrane called 
HA synthases (HAS1-3). The synthesized HA can perform a variety of functions by binding 
to cell surface receptors, affecting cell proliferation, adhesion, migration and invasion. HAS 
uses UDP-Glucuronic acid (UDP-GlcUA) and UDP- N-acetyl-D-glucosamine (UDP-
GlcNAc) to synthesize HA. 
Increased content of HA is seen in many cancers but its exact role and mechanism behind the 
tumor formation is still not clear. High expression of different HASs is also reported in many 
tumors. The aim of our work is to study the effect of substrate availability on intracellular 
trafficking of HAS3 and to investigate its role in controlling HA synthesis. For this purpose 
we have used chemical agents (4-methylumbelliferone and Mannose), which can alter the 
levels of UDP-sugars. We have also explored the possible effect on HAS3 endocytosis and 
recycling endocytosis. Other HA dependent functions like cell proliferation and migration are 
also studied. 
Dendra2-HAS3 is a photo convertible protein constructed to study the traffic of HAS3. MV3 
metastatic melanoma cell lines with transient or stable transfection were used in this study. 
Live cell imaging with confocal microscope were employed for the trafficking experiments. 
Bio-Image XD, a new imaging software was used to analyze the trafficking data. 
The major findings in our experiments demonstrated that alteration of UDP-sugars (by 4-MU, 
Mannose) resulted in significant reduction of HAS3 trafficking from Golgi to Plasma 
membrane, which in turn reduced the HA synthesis. In a similar way the endocytosis of 
Dendra2-HAS3 was increased and significant reduction of HAS3 recycling endosomes were 
also noticed. Other HA dependent biological functions like proliferation and migration were 
also affected by the same chemical agents. Mannose significantly reduced the cell 
proliferation rate and slightly increased the migration, whereas 4-MU had only a mild effect 
on proliferation and migration. On the other hand, Thiamet G which can prevent the removal 
of GlcNAc modification from serine and threonine residues in O-GlcNAc modified proteins 
including HAS3 had no impact in these experiments, with the exception of reducing HAS3 
recycling vesicles. 
From the above results it can be concluded that UDP-sugar substrates of HA have a direct 
connection with HAS3 traffic, which plays a key role in controlling the HA synthesis, 
endocytosis and recycling of HAS3. 
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ABBREVIATIONS 
 
A2aR  adenosine A2a receptor 
CD44  cluster of differentiation 44 
DMEM  Dulbecco´s modified Eagle´s medium 
DNA  deoxyribonucleic acid    
ECM                        extracellular matrix 
ER                           endoplasmic reticulum 
ELSA                      enzyme-linked sorbent assay 
EGF                         epidermal growth factor 
EGFR                       epidermal growth factor receptor 
EGFP                       enhanced green fluorescent protein 
GlcN                       glucosamine 
GAG                       glycosaminoglycan 
GTPase                    guanosine triphosphatase 
GFAT1                    glutamine fructose-6-phosphate amidotransferase 
FGF                         fibroblast growth factor 
HA                          hyaluronan, hyaluronic acid 
HAS                       hyaluronan synthase 
HYAL                     hyaluronidase 
HARE                     hyaluronan  receptor for endocytosis 
HYALP1                hyaluronidase pseudogene 1 
HABPs                    hyaluronan binding proteins  
HCE                       human corneal epithelial cells  
KGF                       keratinocyte growth factor 
LYVE-1                   lymph vessel endothelium receptor 
LMW                      low molecular weight  
LMM                     low molecular mass             
4-MU                      4-methylumbelliferone 
MAPK                    mitogen activated protein kinase  
MβCD                     methyl-β-cyclodextrin   
MCB                      metaplastic carcinomas of breast      
PM                         plasma membrane 
PKC                       phosphokinase 
PFA                       paraformaldehyde 
RHAMM                receptor for hyaluronan mediated motility 
ROI                        region of interest 
RT                         room temperature  
SOD3                     superoxide dismutase 
siRNA                    small interfering ribonucleic acid 
TGF                        transforming growth factor 
TIMP                     tissue metalloproteinase inhibitor 
TSG                        tumor suppressor gene 
TLR                        toll like receptor  
Tf                           transferrin 
Tf R                      transferrin receptor 
UVB                       ultraviolet B 
UDP                       uridine diphosphate 
UDP-GalNAc        uridine diphosphate N-acetlygalactosamine 
UDP-GlcUA          uridine diphosphate glucuronic acid 
 
 
 
UGDH                   uridine diphosphate-glucose-6-dehydrogenase 
UDP-Glc               uridine diphosphate glucose 
UDP-HexNAc       uridine diphosphate N-acetylhexosamine 
UDP-GlcNAc uridine diphosphate N-acetly glucosamine 
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1. INTRODUCTION 
 
Human body is made up of cells which are surrounded by the extracellular matrix, providing 
structural and biochemical support to the surrounding cells. Hyaluronan is one of the 
important components of extracellular matrix. It is a large poly saccharide belonging to the 
glycosaminoglycan group of carbohydrates and is abundantly found in vertebrate tissues. 
Hyaluronan performs a vast variety of biological functions; it is involved embryogenesis, cell 
differentiation, wound healing and inflammation. Hyaluronan expression levels are altered in 
many cancers, thus making it as an important molecule in cancer research. 
Unlike other glycosaminoglycans, hyaluronan is not synthesized in Golgi and instead it is 
synthesized in plasma membrane by a group of enzymes called hyaluronan synthases. 
Hyaluronan synthases in the plasma membrane utilize uridine diphosphate sugars to 
synthesize hyaluronan, these sugars molecules acts like building blocks for the hyaluronan 
molecule. The kinetics of these enzymes are believed to play a key role in controlling the 
hyaluronan production. These enzymes have been shown to play a prominent role in many 
cancers.   
The role of hyaluronan synthases in cancer is very complex and yet a lot of studies have to be 
done to understand its nature in tumor formation. A part from hyaluronan synthase expression 
level, the molecular weight of hyaluronan can either enhance the tumor progression or it can 
also acts as a protective agent against cancer invasion. These unique features of hyaluronan 
make it as an interesting molecule in cancer biology. 
The present study mainly focuses on the role of substrate supply in the intracellular traffic of 
hyaluronan synthase 3 from Golgi to plasma membrane and its influence on hyaluronan 
synthesis. Similarly we have also studied whether the substrate supply can also affect the 
endocytosis and recycling of hyaluronan synthase 3. In addition we have examined the 
consequent, hyaluronan-dependent functions like cell proliferation and migration. 
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2. REVIEW OF LITERATURE 
2.1. Structure and properties of hyaluronan 
Hyaluronan (HA) is a high molecular weight linear polysaccharide made up of repeating 
units N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic acid (GlcUA) units linked by β 
(1-4) and β (1-3) bonds (Laurent et al. 1996).  
 
   
 
 
 
 
 
 
  
Figure 1. Chemical structure (repeating disaccharides) of HA (Kapoor et al. 2011) 
HA was first discovered in the vitreous body of the bovine eye in the year 1934 by Meyer and 
Palmer (Meyer et al. 1934). HA belongs to glycosaminoglycan (GAG) family and it does not 
contain any sulphate groups like other GAGs. Unlike other GAGs, HA is  not synthesized in 
the Golgi apparatus but in the cytoplasmic side of plasma membrane and is simultaneously 
extruded out in to the extracellular space (Weigel et al. 1997). 
HA is an important constituent of the extracellular matrix (ECM), found in variable amounts 
in all tissues of the human body, especially abundant in skin, synovial fluid and the vitreous 
of the eye. HA among the other ECM molecules is very unique with its hygroscopic and 
viscoelastic properties. HA with such features have been broadly used in many medical 
applications as well (Hargittai 2008). HA can also interact with other ECM molecules 
through different cell surface receptors (Chen et al. 1999).  It is also a major structural 
component of the proteoglycan aggregates that are found in many extracellular matrices.  
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HA usually exerts its effects by binding to its cell surface receptors and forms a pericellular 
matrix or coat that affects cell signaling, adhesion, proliferation, migration and tumor 
invasion (Toole et al. 2004). 
2.2. Hyaluronan synthesis 
2.2.1. Mechanism of hyaluronan biosynthesis 
HA is synthesized by glycosyltransferases called hyaluronan synthases (HAS). HAS uses the 
precursor sugars UDP-GlcNAc and UDP-GlcUA to synthesize HA. A single protein utilizes 
both the sugar substrates to synthesize HA. 
 
 
 
Figure 2. Hyaluronan biosynthesis by hyaluronan synthases occurs by addition of the 
sugars N-Acetyl-glucosamine and glucuronic acid ( Hascall et al. 2009) 
HAS enzymes are synthesized in the endoplasmic reticulum (ER) and transported to plasma 
membrane (PM) by transport vesicles along the usual ER-Golgi pathway. In the plasma 
membrane, HAS uses UDP-sugar precursors to synthesize HA ( Hascall et al. 2007). HAS 
enzymes possess more than one binding sites to anchor the growing chain of HA molecule 
and  move the polymer through a pore to export the HA molecule being synthesized in to  the 
extracellular space ( Weigel et al. 1997). 
 
      UDP-GalNAc 
      UDP-GlcUA  
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2.2.2. Hyaluronan synthases (HAS) 
HAS genes are highly homologous and they are located in chromosomes 19, 8 and 16 
respectively. The DeAngelis group were the first to clone Streptococcal HAS-A gene 
(DeAngelis et al. 1993). There are three hyaluronan synthase proteins present in humans and 
they are designated as HAS1, HAS2, and HAS3 (Itano et al 2008). All the three HAS are 
multi-spanning plasma membrane (PM) proteins which show 55-71% identity at amino acid 
level, with HAS2 and HAS3 being most closely related. 
2.2.3. Characteristics of hyaluronan synthases 
Although all HASs (1-3) produce HA, these membrane proteins are known to be somewhat 
different and each HAS isofrom have a distinct biological significance. HAS3 produces 
shorter HA molecules than HAS1 and HAS2.   
HAS may interrelate with the cytoplasmic or plasma membrane proteins which influence 
their catalytic activity (Brinck et al. 1999). All the genes of these isoenzymes have distinct 
promoter regions controlled by a specific signal cascade (Monslow et al. 2003). The 
expression pattern of HAS genes varies in different cell lines and tissues. HAS1 gene is the 
first identified and it may uphold the basal HA production. HAS2 is the major source of HA 
and also best studied of all HASs. Changes in HAS2 expression could lead to major changes 
in HA production and cell phenotype. HAS3 is the somewhat later discovered newly 
discovered enzyme among the HASs and is responsible for the production of both secreted 
and cell-associated forms of hyaluronan (Liu et al. 2001a). HAS3 induces the formation of 
microvilli-like protrusions and it is believed that HA is synthesized in these protrusions  
(Rilla et al. 2008b). 
HA functions are dependent on the enzymatic properties of HASs. HA ability to produce a 
cell surface coat is largely influenced by the enzyme producing it. Rat fibroblasts  transfected 
with the different HASs produce HA coat but the coat formed by HAS1 is smaller compared 
to those by HAS2 and HAS3 ( Itano et al. 1999a). On the other hand, the exact nature of 
HAS1, HAS2 and HAS3 are not quite clear yet. 
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2.3. Regulation of hyaluronan synthesis 
There are many endogenous factors and synthetic compounds known to regulate HA 
production. The HA production levels are altered in many physiological and pathological 
conditions including inflammation, wound healing and cancer. 
Table 1. Factors affecting HA synthesis. Modified from (Kultti 2009a) 
AGENT CELL/TISSUE  HA HAS1 HAS2 HAS3 REFERENCE 
Full-length 
adiponectin 
Fibroblast ↑ NE ↑ - Akazawa 2011 
EGF Fibroblast ↑ ↑ ↑ ↑ Yamada 2004a 
EGF Keratinocyte ↑ - ↑ ↑ Pasonen-
Seppanen 2003 
EGF Oral mucosal cell ↑ ↑ ↑ ↑ Yamada 2004a 
EGF Lung adenocarcinoma 
cell 
↑ NE ↑ ↑ Chow 2010 
Glucose Mesangial cell ↑    Zoltan-Jones 
2003 
IL-1β Fibroblast ↑ ↑ ↑ ↑ Kaback 1999 
Progesterone Uterine fibroblast ↑ ↓ ↓ ↑ Uchiyama 2005 
Prostaglandin 
D2 
Orbital fibroblast ↑ ↑ ↑ ↑ Guo 2010 
TGF-β Synoviocyte ↑ ↑ - ↓ Stuhlmeier 2004a 
Mannose Keratinocyte ↓    August 1994 
4-MU Breast cancer cell 
MCF-7 
↓ NE ↓ - Kultti 2009 
4-MU Melanoma cell ↓    Yoshihara 2005 
4-MU Smooth muscle cell ↓ ↓ ↓ ↓ Vigetti 2009 
 
 
The expression levels of HAS enzymes is the first and very important regulator of HA 
synthesis. HA synthesis may change in parallel with the level of HASmRNA. Another factor 
which can influence the HA synthesis is the post-translational modifications of HAS proteins 
and the traffic of HAS from the ER to Golgi to the plasma membrane. Once the HAS reaches 
 ↓ decreased, ↑ increased, - not changed, NE not expressed and empty not studied 
14 
 
 
the plasma membrane they are most likely activated by phosphokinase C (PKC) pathway 
(Wang et al. 2004). Recent studies particularly on phosphorylation, ubiquitination and O-
GlcNAcylation of HAS show that post-translational modifications can modify its enzymatic 
activity ( Hascall et al. 2014). Post-translational modifications can also influence HAS traffic 
but very little is known about this ( Tammi et al. 2011). HA synthesis uses large quantities of 
UDP-GlcUA and UDP-GlcNAc, so depletion in these UDP sugars can affect the HA 
production (Pitsillides et al. 1993) (Rilla et al. 2013). 
2.3.1. Regulation of hyaluronan synthesis by intracellular trafficking of hyaluronan 
synthases 
The enzymatic activity of the HAS is controlled by its plasma membrane localization, 
possible posttranslational modifications along with the interactions of other membrane 
components and trafficking of the enzyme (Ohno et al. 2002). The distribution of HAS varies 
depending on its isofrom and cell types, but significant proportions of total HAS reside in 
ER-Golgi area. Studies have shown that both over expressed and endogenous HAS are 
localized in the ER-Golgi complex, at the plasma membrane and its protrusions. The 
inhibition of vesicular traffic from Golgi to plasma membrane has reduced the residence of 
GFP-HAS in the plasma membrane and HA synthesis was inhibited, indicating that the HAS 
trafficking proceeds through this organelle. The same study also reported that by addition of 
an enzymatically inactive, missense and C-terminally truncated mutants, GFP-HAS3 were 
not detected in the plasma membrane (Rilla et al. 2005). 
The HA synthesis inhibitor 4-MU (4-Methylubelliferone) prevents localization of HAS at the 
plasma membrane indicating that HAS activity is coupled to its plasma membrane residence 
(Rilla et al. 2005). HA synthesis requires UDP-sugars and their depletion  can affect the HAS 
traffic and the presence of HAS in the plasma membrane crucial for the HA synthesis. 
Recently published studies have shown that Rab10 GTPase is the first protein involved in the 
control of HAS3 traffic. Rab10 silencing increases the plasma membrane residence of HAS3, 
resulting in an increase in HA secretion and also pericellular HA coat (Deen et al. 2014). This 
suggests the importance of intracellular traffic to/from plasma membrane, which is crucial for 
the synthesis of HA. 
The microenvironment play an important role for both HAS activity and   production of HA, 
in which the activity of HAS is phospholipid-dependent. Kakizaki et al have studied the 
distribution of cardiolipins which induce HA synthesis in bacteria. The addition of 4-MU has 
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changed the distribution of cardiolipins in bacterial cells. On the other hand, addition of 
exogenous cardiolipins restores HAS activity in bacterial cells (Kakizaki et al. 2002). 
 2.3.2. Role of UDP substrates in HA synthesis 
 HA synthesis is very unique among the other proteoglycans. HA synthesis requires activated 
nucleotide sugars, UDP-GlcUA and UDP-GlcNAc. The availability of these UDP substrates 
plays a pivotal role in the production of hyaluronan. Once synthesized these UDP sugars are 
transported to the Golgi where they are used as building blocks for various glycoproteins, 
proteoglycans and glycolipids. 
 
 
Figure 3. Main metabolic pathways related to the UDP-sugars precursors of hyaluronan  
(Vigetti et al. 2014) 
Each HAS (1-3) requires different levels of UDP sugars. HAS1 require high cellular UDP-
GlcNAc concentrations than HAS2 and HAS3 to synthesize HA in COS-1 cells (Rilla et al. 
2013). Altered levels of UDP sugars levels can directly affect the synthesis of HA (Jokela et 
al. 2008a) (Clarkin et al. 2011).  
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2.3.2.1.  Alterations of UDP sugars 
There are few chemical agents which can alter the UDP sugar levels, 1) 4-MU  2) Mannose. 
Both these have different mechanism of action in altering the UDP sugar moieties. 
4-Methlylumebelliferone (4-MU) is a coumarin derivative which is a potent HA synthesis 
inhibitor reported in many studies. 4-MU decreases the HA synthesis and also down regulates 
the enzyme HAS (2-3). The study was conducted in melanoma cells and the mechanism by 
which 4-MU decreases HA synthesis through cellular depletion of UDP-Glucuronic acid. 
Apart from HA synthesis inhibition 4-MU significantly decreases cell migration, proliferation 
and invasion, thus adding the importance of HA synthesis in cancer (Kultti et al. 2009a). 
Mannose, a sugar monomer plays an important role in the metabolism of gylcosylation of few 
proteins. Mannose decreases HA synthesis in a dose-dependent way. The dose dependent 
effect of mannose on HA synthesis in cultured epidermal keratinocytes; mannose reduces the 
cellular concentration of UDP-N-acetlyhexosamines (UDP-HexNAc,i.e.UDP-N-
acetlyglucosamine and UDP-N-acetyl-galactosamine) (Jokela et al. 2008a). Based on this 
finding mannose can be a potential chemical in studying the hyaluronan dependent functions 
like cell proliferation, migration and invasion. 
2.3.2.2.  Degradation of hyaluronan 
 The HA degradation depends on different tissues and it is suggested to be as crucial as HA 
synthesis In human body, a third of total HA content is removed and replaced every day 
(Fraser et al. 1981). The exclusion of HA is fast in the epidermis with the half life of  about 
one day ( Tammi et al. 1991) while the half-life of HA is several weeks in cartilage (Morales 
and Hascall 1988). 
The enzymatic degradation of HA can occur by three types of enzymes hyaluronidase 
(HYAL), b-D-glucuronidase and β-N-acetyl-hexosaminidase. These enzymes are distributed 
throughout the body in various forms (Schmidt and Leach 2014). But very little is known 
about the exact mechanism of the HA degradation, although they play a crucial role in tissue 
homeostasis (Lokeshwar et al. 2002). 
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2.3.3. O-GlcNAc Modifications and its effects on HA synthesis 
HAS uses both UDP-GlcUA and UDP-GlcNAc to synthesize HA. UDP-GlcNAc plays an 
interesting role in HA synthesis and cellular energy metabolism. Alterations in the UDP-
GlcNAc are supposed to affect HA synthesis and O-GlcNAc signaling of proteins as well.           
O-GlcNAcylation is a reversible post translational modification of serines/threonines, this 
processes is controlled by two enzymes called O-GlcNAc transferases (OGT) and O-GlcNAc 
hydrolase (OGA) which can effect many biological functions like gene expression. UDP-N-
acetlyhexosamines controls HAS2 expression by altering O-GlcNAc modifications. 
Transcriptional factors like SP1 (Specificity protein 1) and YY1 (Yin-Yang 1) upon 
inhibition by siRNA inhibits the HAS2 expression. Increased or decreased levels of these 
proteins have a direct influence HAS2 mRNA expression (Jokela et al. 2011). 
 
 
UD 
      
          
                                                                                                                          
 
 
 
Figure 4.UDP-sugars undergoing post translational modifications: HAS using UDP-sugars to 
synthesize HA and UDP-GlcNAc undergoing post translational modifications in the presence of OGT 
and later its again modified by OGA. Thiamet G (TG) inhibits the O-GlcNAc hydrolyses. 
 
 
 
UDP-GlcUA UDP-GlcNAc 
Protein Protein 
 
OGT OGA 
HAS 1-3 
   HYALURONAN 
      
Thiamet G 
Ser/Thr 
O-GlcNAc 
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2.3.4. Hyaluronan and its cell surface receptors 
HA is a unique molecule in many aspects, one reason could be because of its remarkable 
physical properties. HA upon binding to its cell surface receptors can perform a variety of 
functions. HA can be able to bound and interact with a variety of proteins called hyaladherins 
(hyaluronan binding proteins (HABPs), HA binding proteins), some of which are receptors 
having signaling properties.  Some of the important hyaladherins are CD44 (cluster of 
differentiation 44), RHAMM (receptor for HA-mediated motility), HARE (Hyaluronan 
receptor for endocytosis) and Lymph vessel endothelium receptor 1 (LYVE-1). 
 
  
 
Figure 5. Hyaladherin family of proteins (Entwistle et al. 1996) 
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Table 2. Hyaluronan interactions with different hyaladherins 
 
S.N
O 
 
Name of the 
Hyaladherins 
 
Effects reported 
 
Reference 
 
1. 
 
HA-CD44 
interactions 
1. Main receptor for HA and its function is 
controlled by its posttranslational modifications. 
2.Activates various signaling cascades associated 
with migration, proliferation, cell invasion and 
tumor progression 
3. Involved in the endocytosis of HA 
 
(Bourguignon 
2008) 
 
2. 
 
 
RHAMM 
1.Acts as an extra cellular binding protein 
2. Influences several signaling cascades 
associated with cell motility and proliferation. 
 
(Hall et al. 1994). 
 
3. 
 
HARE 
1. Highly expressed in the liver endothelial cells. 
2. HARE acts as a clearance receptor for HA and 
also for other glycosaminoglycans. 
(Kyosseva,Harris,
and Weigel 2008) 
 
4. 
 
LYVE 
1. Found in the endothelial cells of lymph 
vessels, binds to HA for degradation. 
(Jackson 2004) 
 
 
2.4. Effects of hyaluronan on other cellular functions 
Biological functions of hyaluronan 
Once synthesized HA can perform a variety of functions because of its exclusive 
physicochemical and biological properties. For decades it was just believed to be as space 
filler but more specific roles have been identified later. HA has strong water retaining ability 
even at lower concentrations and forms a viscous hydrated gel. HA can occupy a volume of 
1000 times the space of HA molecule itself (Hargittai et al 2008).  
HA plays a prominent role in skin physiology as a protectant against the ultraviolet radiation. 
It also controls tissue hydration as it has excellent water retaining ability and forms a viscous 
hydrated gel. HA is widely used ophthalmic application as well because of its rheological 
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property (Chen et al. 1999). Wound healing properties of HA reveals that external application 
of HA in rats has shown quick recovery from the oxidative injury (Foschi et al. 1990). HA 
when interacts with its cell surface receptors accelerates several malignant properties.  
HA-CD44 interactions are important in activating many signal pathways which include 
cytoskeleton changes, that can promote cell proliferation and invasion ( Toole et al. 2009). 
CD44 along with RHAMM can potentiate HA signaling and contribute in growth factor 
regulated signaling (Turley et al. 2002) . 
2.4.1. Pericellular hyaluronan coat 
HA forms a rich pericellular coat or matrix, also termed as “glycocalyx”. Cells with HA 
dependent coat such as fibroblasts, chondrocytes and cancer cells are known to have 
pericellular coats sometimes exceeding 20µm in thickness (Rilla et al. 2008a). Studies have 
shown that thickness of the HA coat influences its interactions with its substrates (Cohen et 
al. 2007). The size of HA-dependent coat is directly proportional to HA production 
(Pienimaki et al. 2001). High expression of HASs has directly influenced the pericellular coat 
formations ( Itano et al. 1999b). Pericellular hyaluronan coat has got multiple roles of both 
structural and mechanochemical functions to regulate cell division, motility, metastasis and 
progression. 
Hyaluronan pericellular coat can directly or indirectly influence on assembling other ECM 
components, by interacting with other pericellular matrix constituents and other matrix 
proteins. HA coat is seen in many different cell lines. Some cell lines have natural hyaluronan 
coat (Rilla et al. 2008a), other cell lines produces HA coat in response to over expression of 
HAS (Kultti et al. 2006). Since the size of HA coat  directly correlates to HA synthesis, 
inhibition of HA synthesis by 4-MU has reduced the coat formation (Kakizaki et al. 
2004)(Kultti et al. 2006). 
2.4.2. Proliferation 
In many studies HA dependent pericellular coat is generally associated with the proliferation 
rate both in in vivo and in vitro (Toole et al.997), but the affect may depend on the cell type. 
HA production initiated either by HAS2 or HAS3 decreases the cell proliferation in 
adenocarcinoma cells (Bharadwaj et al. 2011). HA usually binds to its cell surface receptors 
to perform various biological functions, so changes in binding mechanism could alter the 
expected function including proliferation. HA oligosaccharides inhibited the HA cell surface 
binding and  prevented the formation of peri cellular matrix, which resulted in significant 
21 
 
 
reduction in cell proliferation (Evanko et al 1999). HAS over expression effect on 
proliferation rate is also dependent on cell type. HAS3 over expression increases the 
proliferation in prostate cancer cells (Liu et al. 2001b). Supporting to the above report,   
HAS2 suppression genes by antisense HAS constructs or HAS siRNA inhibits proliferation 
in osteosarcoma cells (Nishida et al. 2005). Contradictory to the above literature, sulfated HA 
derivates  decreases the cell proliferation in rat osteoblasts (Kunze et al. 2010) .  
 External addition of HA in rabbit synovial cells inhibits proliferation and the effect is 
depended on the molecular weight and concentration of HA added in the culture medium 
(Goldberg and Toole 1987). 
2.4.3. Migration 
HA has been shown to increase cell migration in many different cell types. HA creates a 
pericellular matrix like network which facilitates migration of cells. HA is  accumulated by 
the smooth muscle cells leading to an increase in migration during the wound healing (Savani 
et al. 1995). HA induces cell migration in fibroblasts by interacting with the associated ligand 
receptors (Hayen et al. 1999). HA synthesis is often associated with cell migration, decrease 
in migration rate is reported when cells are treated with HA inhibiting agents like 4-MU and 
mannose (Rilla et al. 2004)(Jokela et al. 2008a). 
Keratinocyte growth factors (KGF) a member of fibroblast growth factor (FGF) shown to 
play a role in controlling various cell biological functions, its expression is strongly up 
regulated in wounded epidermis which can initiate cell migration and proliferation and rapid 
increase of HAS2 mRNA. This suggests the direct influence of KGF on the HAS genes 
(Karvinen et al. 2003). HA interactions with CD44 along with the activation of mitogen-
activated protein kinase (MAPK)  increases the cell migration in tubular cells (Ito et al. 
2004). 
HAS induction in HA producing CHO cells have shown to reduce cell migration, adhesion 
and proliferation (Dübe et al. 2001). The role of HA on cell migration is not fully understood, 
contradictory results of HA induced migration could be because different sources of HA. 
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2.4.4. Invasion and metastasis 
Invasion and metastasis are the primary clues in many types of cancer and the knowledge 
about understanding the molecular mechanisms involved in these processes are highly 
valuable.HA levels and HAS expression are shown to increase cell invasion and metastasis in 
many cell types. HAS2 enzyme enhances breast cancer invasion by suppression of tissue 
metalloproteinase inhibitor 1 (TIMP-1), and the same study also reported that total 
knockdown of HAS2 has completely suppressed the invasive capability of these cells by the 
induction of (TIMP-1) (Bernert et al. 2011). Invasion of tumor cells in the ECM is the 
fundamental process in tumor growth and metastasis. HA mediates invasion by interaction 
with its cell surface receptors, HA-CD44 interaction has been observed in colon cancer cells 
which facilitates HA dependent cell invasion (Kim et al. 2004). 
The molecular mechanism behind the HA dependent invasion and metastasis is still not quite 
clear but cell-cell and cell-matrix adhesion and degradation of ECM are likely to play a key 
role (Alberts et al. 2002). 
2.4.5. Effects of hyaluronan and hyaluronan fragments on inflammation 
Functions of HA are mainly size dependent, HA oligosaccharides of different lengths have 
variable effects and even opposite functions. This size dependent function of HA makes it a 
very versatile molecule in matrix biology. HA fragments have shown its influence in tumor 
growth, gene expression and inflammation. 
Low molecular weight (LMW) hyaluronan plays a key role in enhancing lung inflammation. 
LMW HA down regulates adenosine A2a receptor (A2aR) which protects the tissue from 
immune responses and therefore promotes inflammation (Collins et al. 2011). High molecular 
weight hyaluronan has anti-inflammatory effects (Delmage et al. 1986) and hyaluronan 
oligosaccharide show pro-inflammatory effects (Stern et al. 2006). HA during inflammation 
is able to form cables that bind to leukocytes which then recruits inflammatory cells at the 
site of inflammation ( Motte et al. 2009). Anti-inflammatory effects of HA have also been 
reported. HA acts as an anti-inflammatory agent on ethanol induced damage in skin cells 
(Neuman et al. 2011) . HA can also affect inflammation by its influence on cell proliferation 
and migration. 
HA oligosaccharides can deactivate tumor macrophages, whereas high molecular weight HA 
has prevented binding of leukocytes on tumor cells (Fresno et al. 2005).  
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2.4.6. Apoptosis 
Hyaluronan function in apoptosis is much classified, it influences apoptosis in various cell 
types but the results are controversial to one another. HA with high molecular weight is 
shown to induce apoptosis in activated T cells (Ruffell et al. 2008) and also in macrophages 
(Sheehan et al. 2004). HA surface receptor CD44 regulates tumor metastasis and promotes 
tumor cell survival in the tissue and its suppression can regulate apoptosis of the invading 
tumor cells (Yu et al. 1997).  
HAS is also associated with cancer progression and apoptosis. Inhibition of HAS3 expression 
has been shown to decrease the tumor growth in colon cancer cells and increase apoptosis. 
This data suggest that silencing HAS3 correlates with apoptosis (Teng et al. 2010). The effect 
of HA can also be size dependent, low molecular mass (LMM) hyaluronan has induced 
inflammatory neutrophil apoptosis in mice lung (Leu et al. 2011). The role of HA in 
apoptosis in granulosa cells with respect to CD44 connection has reported that HA inhibits 
apoptosis in granulosa cells and this effect can be altered by using anti-CD44 antibody which 
prevented HA from inhibiting the apoptosis (Kaneko et al. 2000). In contrary to the above 
findings Yang and group reported that HA has induced apoptosis in dendritic cells. HA 
expressed by gliomas has contributed that their immunosuppressive effects by enhancing 
apoptosis among other antigen presenting cells (Yang et al. 2002). 
In vivo studies have been done to evaluate effects of HA on apoptosis. In a study conducted 
by Takahashi et al the effect of HA on chondrocyte apoptosis was done in rabbits and its 
reported that HA protects against chondrocyte apoptosis during the development of 
osteoarthritis model (Takahashi et al. 2000). 
2.5. Hyaluronan and cancer 
2.5.1. Hyaluronan expression in cancer 
For decades HA was thought to be space filler but its specific role in cancer development has 
just started to know since a decade. HA role in cancer biology is enormously complex. Once 
synthesized, HA interacts with several cell surface receptors (CD44, RHAMM) and is known 
to influence multiple signal pathways, including those involved in cancer progression and 
pathogenesis. HA and CD44 interactions have enhanced the cancer cell proliferation and 
migration in breast cell carcinoma (Götte et al. 2006).  
HA accumulation is seen in many human tumors (Setälä et al. 1999) and several animal 
models (Simpson et al. 2002) of cancer and in cancer cell lines as well. The content of HA 
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found in these tumors significantly vary with the normal tissue. Higher HA content is shown 
in the tumors originating from the simple epithelia such as breast, ovarian, prostrate, bladder, 
gastric and colorectal cancers.  
Studies have shown that HA dependent biological functions vastly vary with size, molecular 
weight and tissue models. HA derivatives have clearly shown to encourage tumor 
angiogenesis by activating monocyte and macrophages (Sironen et al. 2011). 
HA can enhance the tumor progression and it can also act as a protective agent. In a recent 
study reported that high molecular mass HA has mediated cancer resistance in naked mole rat 
(Tian et al. 2013a). These finding could lead to new cancer prevention techniques for 
humans. HA has unique hydrodynamic properties and it interacts with various HA binding 
macromolecules organized in pericellular and extracellular matrices which in turn can 
influence many cellular functions. HA production leads to the formation of a pericellular coat 
around the cell, which has shown to protect the cells from cytotoxic cells (Gialeli et al. 2011). 
These unique features of HA makes it as a fascinating molecule in cancer biology. 
2.5.2. Hyaluronan synthases and cancer 
All HASs (1-3) are playing a noticeable role in all stages of cancer metastasis and research 
has shown that different HASs can affect metastasis in various pathways. HA content varies 
in different cancers, and so the possible alterations and expression patters of hyaluronan 
synthases are studied to understand the mechanism of HA synthesis. The influence of HASs 
in cancer is yet to be understood and still a lot has to be studied on HAS expression in clinical 
tumors. High expression of HAS1 mRNA levels was reported in bladder cancer tissues 
(Kramer et al. 2011). HAS1 gene over expression was reported to enhance the tumors in 
breast cancer cells, showing that HAS1 plays role in cancer progression ( Itano et al. 2004). 
HAS1 can also play an important role in HA dependent inflammatory response (Stuhlmeier 
2007) but HAS1 requires higher cellular concentration of UDP sugars compared to HAS2 
and HAS3 (Rilla et al. 2013). 
HAS2 which is a major source of HA is shown to promote breast cancer cell invasion by 
suppressing the tissue metalloproteinase inhibitor 1 (Bernert et al. 2011). HAS2 is also 
responsible for the synthesis of high molecular mass HA. Recent findings show that HAS2 
plays an aggressive phenotype of primary breast cancer carcinoma and high HAS2 expression 
levels were found  in metaplastic carcinomas of breast (MCB) (Lien et al. 2014). The 
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expression levels of HASs (1-3) directly correlates with the breast cancer progression and 
also results in poor patient outcome (Auvinen et al. 2014) 
The complete knock down of HAS2 resulted the naked mole rat becomes more susceptible to 
cancer tumors, this suggests that HAS2 can also acts as a cancer protector (Tian et al. 2013b). 
Matrix metalloproteinases (MMPs) plays a key role in cell invasion and HAS2 increases the 
expression of MMP-1 by 340 fold. HAS2 siRNA has shown to decrease the cell induced 
invasion by MMPs (Seppänen et al. 2012). 
HAS3 is the second major source of HA and it is expressed in many tumors. HAS3 over 
expression is shown to promote tumors in prostate cancer cell lines (Liu et al. 2001b). 
Inhibition of HAS3 enzymes with antisense cDNA has showed to result in impaired 
anchorage-independent growth, showing the importance of HA and HAS activity in tumor 
progression (Bullard et al. 2003). Inhibition of HAS3 has decreased the subcutaneous tumor 
growth in colon cancer cells by increasing the apoptosis (Teng et al. 2010). 
A part from HAS expression level, the molecular weight of HA can also influence the tumor 
progression. Elevated HAS3 expression is shown to be an added advantage in the growth of 
tumor formation. Extremely high levels of HASs on inhibition has showed to control the 
tumors, however the role of HAS in tumorigenesis is controversial. 
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3. AIMS OF THE STUDY 
 
Hyaluronan is a unique extracellular polysaccharide with diverse functions. The content of 
HA often plays a key role in different tumors. HASs (1-3) are the enzymes which synthesize 
HA in the plasma membrane by using UDP-sugars. HASs are synthesized at ER and are 
transported to plasma membrane via ER-Golgi pathway. Since the traffic of HASs plays a 
key role HA synthesis. The aim of this thesis is to investigate the role of substrate supply on 
HAS3 traffic and its impact on HA synthesis and HA-dependent cellular functions. 
 
Specific aims of the project: 
 To study the influence of substrate supply (i.e. UDP-GlcUA and UDP-GlcNAc) on 
HAS3 traffic and HA synthesis. Specifically, HAS3 traffic in terms of Golgi-to-
plasma membrane secretory pathway,  endocytosis and recycling endocytosis are 
studied in this thesis work 
 In addition, the influence of HA synthesis-dependent cell biological functions like 
proliferation and migration were investigated. 
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4. MATERIALS AND METHODS 
4.1. Materials 
Cell culture: The cell lines used in this project are MV3 metastatic melanoma with transient 
or stable transfection of Dendra2-HAS3, EGFP-HAS3 and mRFP-HAS3. MV3 cells were 
cultured in Dulbecco´s minimal essential medium (Euroclone), high glucose (4500mg/l) with 
10% fetal bovine serum, 4mM Glutamine, 50µg/ml streptomycin and 50 units/ml penicillin 
(Sigma). The cells were trypsinized with 1ml of trypsin and cultured every 2-3days 
depending up on the confluence of the cells. 
Plasmids and antibodies: EGFP-HAS3 (Rilla et al. 2012) and Dendra2-HAS3 (Rilla et al. 
2013) plasmids are constructed as described previously. The hHAS3 was sub cloned between 
the restriction sites XhoI and HindIII of paGFP-C1 vector. Using the same restriction sites 
hHAS3 cDNA was recovered and sub cloned again in Dendra2-C1 vector to generate 
Dendra2-HAS3 which is a photo convertible protein to be used in the trafficking experiments. 
The construct mRFP-HAS3 was made by sub cloning hHAS3 cDNA in mRFP-C1(Deen et al. 
2014). 
MV3 cells stably expressing EGFP-HAS3: The generation of MV3 cells stably over-
expressing doxycycline-inducible (Sigma) EGFP-HAS3 was described before (Takabe et al 
manuscript (personal communication)). MV3 cells with optimal EGFP-HAS3 expression 
followed by 0.05µg/ml doxycycline (Sigma) induction and maintained in growth media with 
50 µg/ml hygromycin (Invitrogen).The constancy and reproducibility of EGFP-HAS3 
expression in response to doxycycline was determined with HA assays. 
4.1.1. Treatment of cells  
The cells were treated with the following reagents: Doxycycline (Sigma) at 0.05µg/ml to 
induce the HAS3 expression. Transferrin marker (Invitrogen) at 25µg/ml was used to study 
the recycling of HAS3. 4-MU (Sigma) at 0.5 mM was used to inhibit HA synthesis by 
depleting the intracellular UDP-glucuronic acid. Mannose (Sigma) at 20mM depletes the 
intracellular UDP-N-acetlyglucosamine and inhibits HA synthesis. Thiamet G (Cayman 
chemicals) at 10µM is shown protect the O-GlcNAc modification by inhibiting the OGA. 
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 4.2. METHODS 
4.2.1. EXPERIMENTAL SETUP 
Live cell imaging: For photo conversion studies and trafficking assays; Dendra2-HAS3 
transient constructs were used. Live cell plasma membrane markers like Deep mask red 
(Invitrogen) at 5mg/ml are used to study the HAS traffic in plasma membrane. 
Confocal microscopy and live cell imaging: Confocal microscope equipped with Zeiss 
LSM700 is used to obtain fluorescent images with 40x NA 1.3 and 63 NA 1.4 oil objectives. 
For live cell imaging, Zeiss XL-LSM S1 incubator with temperature and CO2 control levels 
were adjusted according to the set up. 
4.2.2. HA SECRETION ASSAY  
MV3-HAS3-EGFP stably expressed cells were selected for HA secretion assay and 40000 
cells were plated in a 24 well plate and in each well of total 10 wells. After 24hrs of plating 
the growth medium was replaced by doxycycline (0.05 µg/ml) medium to induce the 
expression of EGFP-HAS3. After 24 h, of doxycycline treatment the media was replaced 
with fresh DMEM 1% (Serum) and the chemical reagents were prepared and the cells were 
treated with 4-MU, Mannose and Thiamet G with their respective concentrations for another 
24 h. After this step, the media from the chemical groups were collected and stored at -20°C, 
and the cell numbers were counted using a hemocytometer to express the HA content as 
ng/10,000 cells. The amount of HA secreted in the growth medium was analyzed by an 
enzyme linked sorbent assay (HA-ELSA) sandwich method (Hiltunen et al. 2002).  
4.2.2.1. ELSA-like Assay for Hyaluronan 
Sandwich type ELSA method was used to determine the concentration of HA. 96 well plates 
(Maxi sorp, Nunc, Denmark) were coated with 100ul of 0.5ug/ml in 50mM sodium carbonate 
buffer at pH 9.5 to the wells and incubated for 2 h at +37°C. After the incubation period the 
wells are washed 3x3 mins with 200ul 0.5% tween 20 in PBS (Phosphate buffered saline). 
250ul of 1% BSA in PBS is added to block the wells and incubated at +37°C for 1 h. The 
plates are washed again for 3x3 minutes with 250 ul 0.5% Tween 20 in PBS and were stored 
at -20°C for 24 h. 
After the overnight incubation the plates were taken out and kept aside. 100ul of standard and 
the test samples of different concentrations were added in the wells and incubated at +37°C 
for 1 h. The wells are washed with 200ul 0.5% Tween 20 in PBS. 100ul of 1,0 ug/ml of 
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bHABC were added to the wells and incubated at +37°C for 1h. After the incubation the 
plates are again washed with 3x3 minutes with 200ul 0.5% Tween 20 in PBS.  Horse radish 
peroxidase streptavidin (1:20000) was prepared in PBS, 100ul was added in the wells and 
then incubated for 1 h at +37°C.   
In the mean time substrate buffer of 20ml with 0.5% TMB (Tetramethlybenzidine) was 
prepared and 100ul was added in each well. The plates were immediately kept in the dark for 
10 mins at room temperature until blue color is observed in the wells. 50ul of 2N H2SO4 to 
stop the chain reaction and measure absorbance at 450 nm. The standard curve and the HA 
concentration are calculated. 
4.2.3. HAS3 TRAFFIC FROM GOLGI-TO-PM 
MV3 cells was plated in a 8 well chambered well, each well containing 20,000 cells and the 
plate is kept in the incubator at 37°C for 24 hrs. MV3 cells are transfected with Dendra2-
HAS3 (0.5 ug) diluted in 100ul NaCl (150mM) and vortexed.  ExGen 500 transfection 
reagent 3ul (Fermentas, Thermo Scientific, USA) was added to this mixture and vortexed 
immediately. The transfection mixture was incubated at room temperature for 10min. 
Prior to the transfection the cells are washed with 1xPBS and replaced with DMEM 1% 
(Serum). Now we have added 20ul of transfection mixture in each well with uniform 
distribution. The 8 well plates are kept back in to the incubator for 24 h.  
On the next day the MV3 cells transfected with Dendar2-HAS3 are treated with 4-MU (0.5 
mM), Mannose (20 mM) and Thiamet G (10µM) with respect to the controls. DMSO is used 
as a control for Thiamet G. The duration of the treatment was about 6h and after that cells 
were again treated with the same reagents along with the deep mask red (1:4000) and the 
plate was taken to the confocal setup,  adjusted to the according to the experimental 
conditions. The  region of  interest (ROI) is marked  and after bleaching  Dendra2-HAS3 the 
photo was converted with a short pulse of UV-laser illumination (405 nm for 10-20 
milliseconds, 15 iterations, 15% laser strength) into a region of interest i.e. Golgi or cell 
surface, using respective marker dyes i.e. deep mask red (PM). The time point after photo 
conversion was set as “0” and time-lapse images were taken for 60mins with 10min intervals. 
We have tracked the selected photo converted HAS3 proteins by time-lapse imaging from 
Golgi-PM and the kinetics of HAS3 transported vesicles is measured. The fluorescent images 
were obtained with 40x NA 1.4 oil objectives. 
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4.2.4. ENDOCYTOSIS OF DENDRA2-HAS3 
The same experimental design as above was used to study the endocytosis of Dendra2-HAS3. 
MV3 cells after the transfection with Dendra2-HAS3 and after treating with the same 
reagents for 6 h was re-treated again with same chemical reagents along with PM (Deep mask 
red) dye. The plate was taken to the confocal setup and the  region of  interest (ROI) was 
marked , after  the bleaching  Dendra2-HAS3 was photo converted with a short pulse of UV-
laser illumination (405 nm for 10-20 milliseconds, 10 iterations, 15% laser strength) in a 
region of interest i.e. plasma membrane or cell surface, using respective marker dyes i.e. deep 
mask red (PM). The time point after photo conversion was set as “0” and time-lapse images 
were taken for 15mins with 2mins intervals. 
We have tracked the selected photo converted HAS3 proteins by time-lapse imaging from 
PM-inside the cell and the kinetics of HAS3 transported vesicles are measured. The 
fluorescent images were obtained with 40x NA 1.4 oil objectives. 
 
4.2.5. INFLUENCE OF HA SYNTHESIS ON HAS3 RECYCLING BACK TO PM 
4.2.5.1. Recycling assay HAS3 (Fixed cells) 
MV3 cells were plated in 3 different 8 well chambered plates, each well containing 
approximately 20,000 cells. After 24 h the cells were transfected with mRFP-HAS3 and the 
transfection mixture includes DMEM (without additives) and turbofect which were vortexed 
and spun uniformly and incubated at room temperature for 5 mins. The cells are washed with 
1xPBS and replaced with DMEM 1% (Serum) and immediately the transfection medium is 
added in to the wells by uniform distribution and placed carefully inside the incubator. 24 h 
after the transfection the plates were removed from the incubator and treated with 4-MU (0.5 
mM), mannose (20mM), and Thiamet G (10µM) for 6 h time period. After the treatment time 
the plates were kept on an ice plate and the media is replaced by fluorescein-conjugated 
transferrin media (25µg/ml). In this step all the events in the cells are frozen and the plates 
are kept in the refrigerator at +4°C for 20-30mins. Now the cells are taken out and replaced 
with warm DMEM and kept inside the incubator for transferrin internalization.   
All the 3 plates followed the same procedure for internalization with different time points (5, 
10 and 15mins). 
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After allowing the cells to internalize the fluorescein-conjugated transferrin, the cells are 
treated with 4% paraformaldehyde (PFA) for 5-10mins and then washed 3x5mins with PB. 
The cells were later taken to the confocal microscope for imaging. For colocalization 
analysis, images were taken as z-stack sections at 0.39 µm intervals with a 63x oil objective 
and the colocalization between mRFP-HAS3 and the fluorescein-conjugated transferrin was 
analyzed. 
The colocalization analysis was done by Bio-Image XD software (Kankaanpää et al. 2012) 
and the colocalized spots were manually counted in both treated and control group of cells 
and the statistical analysis were done.  
4.2.5.2. Analysis of HAS3 re-cycling by motion tracking (Live cells) 
MV3 cells were plated in 3 different 8 well chambered plates, each well containing 
approximately 20,000 cells. After 24 h the cells were transfected with EGFP-HAS3 (0.5 
ug/ul) and the transfection mixture includes DMEM (without additives) and turbofect which 
were vortexed and spinned uniformly, incubated at room temperature for 5 mins. Then the 
cells are washed with 1xPBS and replaced with DMEM 1% (Serum) and immediately the 
transfection medium is added in to the wells by uniform distribution and placed carefully 
inside the incubator. 24 h after the transfection the cells were treated with mannose (20mM) 
for 6 h duration of time. After the treatment time the plates were removed from the incubator 
and kept on an ice plate for 2-3 mins and the cells are taken directly to confocal microscope 
for live cell imaging and continuous scans were taken for 2 mins time point. 
The images were analyzed by Bio-Image XD software, by using the tool motion tracking. 
This option enabled us to track the individual recycling movement of the track. The typical 
recycling tracks with “C” curve were selected as the ideal recycling vesicles. The first 100 
recycling tracks were analyzed and manually counted in both control and mannose treated 
cells and the average numbers of recycling tracks were calculated. 
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4.2.6. INFLUENCE OF HA SYNTHESIS ON MV3-EGFP-HAS3 ON CELL 
PROLIFERATION 
 
4.2.6.1. Cell proliferation assay (Crystal violet method) 
MV3-HAS3 cells are plated in 3x 96 well plates and each well consisting of 2500 cells/well 
and the cells are incubated for 24 h. Three 96 well plates were chosen for different time 
points (24, 48 and 72 h) of proliferation of the cells. On the next day the chemicals reagents 
(4-MU (0.5mM), Mannose (20mM), Thiamet-G (10µM)) are prepared in the doxycycline 
media (0.05 µg/ml) and the media present in all the plates were replaced by their respective 
chemical media. 
After 24 h of treatment time, 24 h and 48 h well plates were removed from the incubator. The 
media is again replaced by doxycycline media in the 48 h well plate and placed back in to the 
incubator. The 24 h plate under goes fixing procedure, the media was removed and the cells 
are treated with 4% PFA at room temperature for 10-15 min, followed by phosphate buffer 
(PB) washing for (5x 2 min) fixing the cells. The plates were sealed with parafilm and stored 
it in the fridge. 
Similar procedure was followed for 48 h and 72 h plates and the plates are stored in the 
fridge. We have used crystal violet method to analyze the cell proliferation rate. All the plates 
were stained by 0.1 mg/ml crystal violet at room temperature (RT) for 10mins, followed by 
PB (2x2 min) washing. After PB washing the cells in all the plates were treated by 33% 
acetic acid for 5 mins at RT with gentle shaking. Finally the plates are taken to VICTOR 
plate reader and the absorbances of the cells at 570 nm were recorded. 
4.2.7. INFLUENCE OF HA SYNTHESIS ON MV3-EGFP-HAS3 ON CELL 
MIGRATION 
 
4.2.7.1. Migration assay (Scratch wound method) 
MV3-HAS3 cells were plated in 2x12 well plates and each well consisting 160,000 cells. 
After 24 h of incubation the media is removed and the cells are washed with PBS once, and 
the media is replaced by doxycycline (0.05 µg/ml) media and the plates are kept back inside 
the incubator. 24 h after the doxycycline treatment, chemical reagents (4-MU (0.5mM), 
Mannose (20mM) and Thiamet G (10µM) are prepared in the doxycycline media. The cells 
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are now taken out from the incubator and a crosswise cell-free area was introduced with a 
sterile tip. Now the media is replaced by their respective chemical treated media in to their 
wells and the cells were immediately taken to the microscope as zero time point pictures. 
Images were taken in every treated well at different time points (0, 12, 24 h) and the cells are 
taken back to the incubator.  
The migration rate was reflected in the change in the cell fee area measured immediately after 
introducing the wound and then compared with the different time point images. We have 
used NIH Image J software to calculate the average distance that the outermost cells had 
migrated was calculated in pixels that were then converted to micrometers.  
4.2.7.2. Statistical analysis   
In most of the experiments ( Including HA secretion, HAS traffic, recycling , proliferation 
and migration ) we have used one way ANOVA and Tukey´s test to analyze the significance 
differences between control and chemical treated cells. The statistical significance was set at 
p < 0.05. Trafficking experiments was repeated for three times with 5-10 images each. The 
statistical analysis was performed and the experiment was repeated for three or four times. In 
HAS3 colocalization analysis the number of cells taken 3 in each time point and the statistical 
significance was set at p < 0.05, p < 0.01. HAS3 recycling assay (live cells) we have used 
Student´s t test to analyze the significance differences between control and Mannose treated 
cells, with the statistical significance set at p < 0.01.The statistical analysis was performed 
and the number cells taken was 3. In both cell proliferation and migration assay we employed 
one way ANOVA and Tukey´s test to analyze the significance differences between control 
and chemical treated cells. The absorption of crystal violet by the dna in the cells is used to 
analyze the proliferation rate .In migration assay two fields were counted from two replicates 
and the experiment was performed by three times. 
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5. RESULTS 
5.1. SUB-CLONING OF DENDRA2-HAS3 CONSTRUCT 
 
Figure 6. Subcloning and generation of Dendra2-HAS3 construct: Figure shows positive colonies 
of bacteria expressing Dendra2-HAS3 construct. 
hHAS3 was subcloned from EGFP-HAS3 (donor) plasmid to Dendra2-C1(recipient) vector using 
XhoI-HindIII restriction sites. 
The positive clones (Fig 6) were verified by insert dropout assay, where the hHAS3 gene  
was cut using the same restriction enzymes, XhoI and HindIII and confirm the separation of 
hHAS3 gene from the Dendra2 vector background (Fig 7) 
Dendra2-hHAS3 was generated (to be used in trafficking experiments) and pilot experiments 
(i.e. HA coat and secretion, and photo conversion) were carried out in cell lines by transient 
transfection to confirm the presence of hHAS3  
 
  
Dendra2-hHAS3 – 6.4 Kb 
Dendra2 – 4.7 Kb 
 hHAS3 – 1.7 
Kb 
 
 
 
 
Figure 7. Insert drop out analysis of Dendra2-HAS3: Using XhoI-HindIII restriction 
digestion, the presence of hHAS3 (1.7 Kb) was confirmed. 
 
M      U1     D1    U2       D2     M  
 
U1 & U2 – Undigested clones (1, 2)  
 D1 & D2 – Digested clones (1, 2)  
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5. 2. HA SECRETION IN MEDIA WITH THE CHANGE IN SUBSTRATE 
AVAILABILITY AND CHANGE IN O-GLCNAC SIGNALING IN MV3-EGFP-HAS3 
MELANOMA CELLS 
  
 
Figure 8. Effect of different chemical agents altering the availability of UDP sugars and O-
GlcNAc signaling on HA secretion in MV3-EGFP-HAS3 cells: 4-MU and mannose which alter the 
UDP-sugar substrates decreased HA secretion, with latter having a more significant effect. Thiamet G 
which protects the O-GlcNAc modification did not influence HA secretion, compared to control (C + 
DMSO). Mean ± SEM, n = 4; *p < 0.05 (One way ANOVA, Tukey’s test). 
 
Evaluation of different chemical moieties effecting HA secretion. This assay provides the 
information on how much HA was secreted in to the external medium. Compared to the 
control group, Mannose (20mM) significantly decreased HA secretion to almost by 50% (Fig 
8-5.3). 4-MU (0.5mM) also decreased the HA secretion but comparatively less than mannose. 
Thiamet G (10 µM) did not influence the HA secretion. 
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5.3. PHOTO CONVERSION AND TRACKING OF DENDRA2-HAS3 IN LIVE CELLS 
 
               Figure 9. Photoconverstion and tracking of Dendra2-HAS3: Red region of interest (ROI) 
was set around the Golgi in Dendra2-HAS3 transfected MV3 cells and photo activated with 405 nm  
and the traffic of Dendra2-HAS3 red was analyzed in plasma membrane (blue ROI, marked by PM 
dye Deep mask red). The kinetic analysis of Dendra2-HAS3 traffic towards plasma membrane was 
calculated by measuring Dendra2-HAS3 red-to-PM dye ratio. 
 
A photo-convertible protein is needed to study the trafficking of HAS3. Dendra2 is a photo-
convertible protein from green-to-red at 405 nm wavelength. Dendra2-HAS3 (fusion protein, 
result section 1, Fig 2) is thus photo-converted (Fig 9-5.4, see Dendra2-HAS3 (red) panel) 
with a short pulse of UV-laser illumination (405 nm for 10-20 milliseconds, 15 iterations, 
15% laser strength) in a region of interest i.e. Golgi or cell surface, using respective marker 
dyes i.e. deep mask red (PM) (Fig 9-5.4, PM dye panel). 
The ”selected” or ”photo converted HAS3” vesicles over time (time-lapse imaging) to/from 
different sub cellular compartments and measure the kinetics of the transported HAS3 
vesicles. 
PM dye (Deep mask red) 
37 
 
 
5.4. MANNOSE AND 4-MU REDUCED GOLGI-TO-PLASMA MEMBRANE TRAFFIC 
OF DENDRA2-HAS3  
 
 
 
In control cells, the traffic of Dendra2-HAS3 from Golgi to plasma membrane (shown as 
blue border line in the cells) was already visible in 10-30 min (Fig 10 , C + PBS panel) 
and the kinetics almost reach 2-fold increase in 60 min (Fig 10); this can be clearly seen 
in the time lapse images as well (Fig 10, C + PBS), with the intensity of Dendra2-HAS3 
Figure 10 (A). Dendra2-HAS3 was photoactivated in Golgi (red ROI) and the traffic of HAS3 to 
plasma membrane (blue ROI) was analyzed. The presence of HAS3 in PM with different treatments 
at various time intervals was analyzed. (B) Part of the plasma membrane was shown here for better 
clarity and the blue ROI shows the presence of HAS 
  
(A) 
(B) 
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vesicles in and around plasma membrane clearly significant compared to the 0 min time 
point (see “Post” panel in C + PBS, Fig 10) 
4-MU and Mannose have significantly decreased the traffic of Dendra2-HAS3 to plasma 
membrane, which is clearly seen in 60 min time point images (Fig 10, 4-MU and 
mannose panels) 
 
 
 
 
  
(A) 
 
(B) 
Figure 11. Dendra2-HAS3 kinetics with 4-MU, mannose and Thiamet G. (A) (B) 
HAS3 kinetics was measured as explained in Fig.10. Significant decrease of HAS3 traffic 
was observed with 4-MU and mannose with its control (PBS). (B) Similarly Thiamet G 
shown in the different graph within the same experiment did not influenced the traffic 
compared to its control DMSO Mean ± SEM, n = 3-5 (5 images each); *p < 0.05, **p < 
0.01(One way ANOVA, Tukey’s test) 
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When we analyzed the kinetics of Dendra2-HAS3 traffic, there is two-fold increase in HAS3 
traffic within 40-60 min in control cells (Fig 10).4-MU and mannose have significantly 
reduced Dendra2-HAS3 traffic from Golgi to PM, with mannose having a more potent effect 
than 4-MU (Fig 11- A).Compare to its control (Control with DMSO), Thiamet G has no 
effect on Denadra2-HAS3 traffic from Golgi to plasma membrane (Fig 11- B) 
 
5.5. ENDOCYTOSIS OF DENDRA2-HAS3 IS ALSO AFFECTED BY ITS SUBSTRATE 
SUPPLY 
 
  
 
Dendra2-HAS3 endocytosis was analyzed in the presence of 4-MU and mannose, by 
activating HAS3 in plasma membrane (marked by PM dye, deep mask red) and the kinetics 
of HAS3 reduced in plasma membrane is measured and compared between different groups. 
Compared to control, both 4-MU and mannose has influenced HAS3 traffic from cell surface 
to inside of the cells, with mannose even more potent (Fig 12) 
 
 
Figure 12. Dendra2-HAS3 endocytosis with 4-MU and mannose from PM: Dendra2-
HAS3 endocytosis was significantly increased when treated with both 4-MU and 
mannose. Mean ± SEM, n = 5 (9-10 images each) ; t- test (***P < 0.0001) 
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Recycling endocytosis of mRFP-HAS3 with Transferrin 
 
 
Figure 13. HAS3 recycling assay using transferrin as a marker: In order to study the recycling of  
HAS3 the colocalization of mRFP-HAS3 and Fluorescein-transferrin at the cell surface was studied at 
different time points (2, 5, 15 min) with different chemical treatments (i.e. 4-MU, mannose and 
Thiamet G). The colocalization analysis was done by counting the number of colocalized vesicles 
around the PM. Mannose treated cells showed reduced colocalization of mRFP-HAS3 and transferrin 
in all time points (2, 5 and 15 min) treated with mannose 
41 
 
 
5.6. INFLUENCE OF HA SUBSTRATES ON HAS3 RECYCLING BACK TO PM 
 
         
 
 
 
 
HAS3 recycling was analyzed in MV3 cells using fluorescein conjugated transferrin at three 
different time points i.e. 2 min (fast recycling), 5 min (intermediate recycling) and 15 min 
(slow recycling). Control cells showed colocalized vesicles, near cell surface, positive for 
mRFP-HAS3 and transferrin (Fig.13 A) and the quantitative analysis showed ~15-25 positive 
Figure 14. HAS3 recycling  :(a) The graph shows 
the fast recycling and colocalization of vesicles in 
MV3 cells transfected with mRFP-HAS3 and 
treated with transferin in all groups. The 
colocalizations of vesicles were significantly 
reduced in 4-MU, Mannose and Thiamet G 
treatment groups. 
(b) The graph shows intermediate recycling and 
Only Mannose significantly reduced the 
colocalization vesicles. 
(c) Slow recycling graph: Both mannose and 
Thiamet G have significantly reduced the 
colocalization vesicles. Mean ± SEM, n = 3; *p < 
0.05, **p < 0.01 (One way ANOVA, Tukey’s test) 
 
(a) 
(c) 
(b) 
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recycling vesicles in all time points (2, 5, 15 min) corresponding to fast, intermediate and 
slow recycling vesicles (Fig.14 B). 
Mannose treated cells showed significantly reduced vesicles, positive for mRFP-HAS3 and 
transferrin, in all time points (2, 5 and 15 min) (Fig.14 A, B and C) corresponding to fast, 
intermediate and slow recycling pathways; whereas, 4-MU showed reduced vesicles positive 
for mRFP-HAS3 and transferrin only in 2 min, corresponding to fast recycling, but not in 
other time points (Fig.14 A). 
Thiamet G, on the other hand, showed surprisingly reduced vesicles, positive for mRFP-
HAS3 and transferrin, in slow and fast recycling (2 and 15 min) (Fig.14 A and C) 
 
 
5.7. ANALYSIS OF HAS3 RECYCLING BY MOTION TRACKING (IN LIVE CELLS) 
Motion tracks (vesicle movements) in a cell and selected tracks  
 
  
 
Figure 15. Segmentation and tracking of HAS3 vesicles: A) Processed image of the cell showing 
tracks of vesicle moments. B) Processed image shows criteria for the selection of different tracks. 
Track 1 is recycling endosome with C curve track, track 2 is endocytic vesicle and track 3 is Golgi to 
PM vesicle movement. 
Using live cell imaging and analysis of vesicle tracks with BioImageXD software, the 
recycling tracks were manually counted mRFP- or EGFP-HAS3 recycling vesicles and the 
(1) 
(2) 
(3) 
(A) (B) 
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tracks inside the cells (Fig 15 A). We have analyzed 100 fast recycling tracks from each cell 
in control and treated cells (n = 3 from each; time point = 2 min) and scored the percentage of 
fast recycling tracks. The direction and ”C-type” curve of the vesicle tracks near PM were 
selected as recycling endosomes (Fig15 B, track “1”); Other type of vesicular movements like 
endocytosis (Fig 15 B, track “2”) and Golgi-to-PM traffic were excluded based on this 
criteria (Fig15 B, track “3”) . 
 
Mannose decreased recycling of EGFP-HAS3 in MV3 cells 
Control – 57 tracks    (A)                               Mannose – 28 tracks (B)                
   
Figure 16. Recycling tracks of EGFP-HAS3: Recycling endocytosis of EGFP-HAS3 under the 
influence of mannose. (A) and (B) respectively shows the number of recycling tracks of EGFP-HAS3 
in control and mannose treated cells. Reduced number of recycling tracks in a mannose treated cell 
can be appreciated here (B), when compared to control (A). 
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The analyzed EGFP-HAS3 recycling vesicles, as explained above (Results section Fig 15), in 
live cells with only 2 min, continuous acquisition of time-lapse images. Control cells showed 
an average of 50-60 EGFP-HAS3 recycling tracks (Fig 16 A and C). In mannose treated 
cells, significant inhibition of EGFP-HAS3 recycling vesicles was observed to almost half 
(Fig16 B and C). 
 
 
 
 
 
 
 
 
Figure 16 C. Quantitative analysis of EGFP-HAS3 recycling tracks: The recycling of HAS3 
vesicles back to the PM was evaluated by manual counting with the help of BioImageXD 
software. Mannose treated cells have significantly reduced the HAS3 recycling tracks compared 
to control. Mean ± SEM, n = 3 (i.e. 3 images/group); **p < 0.01 (student’s t test). 
 
(C) 
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5.8. INFLUENCE OF HAS SUBSTRATE CONTENT AND O-GlcNAc INHIBITION ON 
MV3-EGFP-HAS3 CELL PROLIFERATION 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Cell proliferation analysis with alteration of HA substrates and O-GlcNAc levels: The 
graph shows the cell numbers (indicated by Crystal Violet absorbance). Compared to control, 
mannose has significantly reduced the proliferation of MV3-HAS3 cells.  Other treatments did not 
significantly influence cell proliferation. Mean ± SEM, n = 3; *p < 0.05 (One way ANOVA, Tukey’s 
test) 
Mannose significantly decreased the cell proliferation of MV3-EGFP-HAS3 cells.                 
4-MU (0.5mM) also decreased the cell proliferation (more prominent at day 3) but not 
significantly like Mannose (20mM). Thiamet G (10 µM) did not influence the proliferation.  
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5.9. INFLUENCE OF HAS SUBSTRATES AND O-GlcNAc MODIFICATIONON MV3-
EGFP-HAS3 CELL MIGRATION 
 
 
Figure 18 . Cell migration analysis with alteration of HA substrates and O-GlcNAc levels:  The 
migration assay was done by scratch wound assay. The graph represents the migration rate between 
different treatments and out of all treatments mannose has increased the migration levels of MV3-
HAS3, mean ± SEM (n = 3). 
 
Mannose increased the cell migration of MV3-EGFP-HAS3 cells. Whereas 4-MU and 
Thiamet G did not influence the migration. 
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6. DISCUSSION 
 
6.1 General Remarks 
The most interesting findings emerging from this study is the regulation of traffic of HASs 
which can directly influence the synthesis of HA. This is the first time a study was conducted 
on HAS3 trafficking to investigate whether alterations in HA substrates i.e UDP-GlcUA and 
UDP-GlcNAc, can affect  intracellular traffic of HAS3 and its influence on HA synthesis and  
cellular functions like proliferation and migration  in  MV3 melanoma cells. 
6.2 Methodological Issues 
In order to study the intra-cellular trafficking of HAS3, the sub cloning humanHAS3 to 
Dendra2-HAS3 was done. This photo-convertible protein was used in studying the 
intracellular trafficking. In our experiments we have used different chemical agents which are 
previously shown to alter the HA synthesis like 4-MU, Mannose and Thiamet G. To study the 
traffic of HAS3 we employed live cell imaging using Zeiss LSM 700 confocal microscope 
and to analyze the images for colocalization and motion tracking we used Bio-Image XD 
software. To analyze the HA secretion in the media, sandwich type ELSA method was used. 
To investigate the influence of HA synthesis on other biological functions in MV3-HAS3 
cells, crystal violet method for proliferation assay and Scratch wound method for migration 
assay were chosen. 
6.3 HA secretion assay  
 4-MU has inhibits the HA synthesis by depleting the cellular UDP-glucuronic acid in 
melanoma cells (Kultti et al. 2009b). Jokela et al reported that Mannose dose dependently 
decreases the HA synthesis. The study also focused on the combined effects of Mannose with 
4-MU and 4-MU alone on effecting the HA synthesis and they have used sandwich type 
ELSA assay to analyze the HA in the media (Jokela et al. 2008b). In our experiments we 
have also used the same assay to measure the HA content. 
In HA secretion assay we have used MV3-HAS3 cell line and both 4-MU and Mannose have 
reduced the HA secretion compared to the control. HA secretion was analyzed using 
sandwich type ELSA (Hiltunen et al. 2002). The decrease of HA secretion with 4-MU is 
comparatively less than Mannose. Whereas Thiamet G did not influence HA secretion (Fig 
5.3). 
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6.4 Intracellular trafficking of HAS3 from Golgi to PM 
To study the influence of HAS trafficking on HA synthesis, Rilla et al reported that  brefeldin 
A, an antibiotic which interferes the vesicular traffic from the Golgi-to-PM has reduced the 
residence of GFP-HAS on the PM and also inhibited HA synthesis suggesting that HAS 
trafficking may proceed through this organelle (Rilla et al. 2005). This shows that HAS 
transport is important for regulation of HA synthesis. Kultti and co-workers reported that 
brefeldin A and 4-MU has suppressed the microvilli-like protrusions induced by GFP-HAS3 
with 4-MU reduces the PM residence of GFP-HAS3 (Kultti et al. 2006). This suggest that 
expression of HAS enzymes is the first and foremost important determinant of the HA 
synthesis. Deen et al recently identified that Rab10 GTPase as the first protein involved in the 
control of HAS3 traffic (Deen et al. 2014). These findings from the previous literature has 
encouraged us to study furthermore (a) To investigate whether alterations in the UDP-sugars 
can affect the traffic of HAS3, (b) The mechanism and machinery involved in the 
intracellular trafficking of HAS3 and its influence of HA synthesis. HA plays a key role in 
tumor progression. This investigation helps in understanding the HA metabolism at the 
molecular level. 
4-MU has previously shown to down regulate HAS2 and HAS3mRNA levels by depletion of 
cellular UDP-glucuronic acid and Mannose as shown decrease the HA synthesis by altering 
the intracellular concentrations of UDP-GlcNAc.  
To study the intracellular trafficking of HAS3, UDP-sugar alterating agents like 4-MU and 
mannose were used. The cellular content of UDP-GlcNAc is usually 3-7 times higher than 
that of UDP-GlcUA ( Itano et al. 1999b) this literature supports our finding as both 4-MU 
and Mannose have significantly reduced the traffic of Dendra2-HAS3 from Golgi-to-PM with 
Mannose having a more potent effect than 4-MU (Fig.11). This results co-relates the HA 
secretion assay where only Mannose has significantly reduced the HA secretion (Fig7) 
compared to 4-MU. On the other hand Thiamet-G did not influence the traffic (Fig 12). 
O-GlcNAc acts as a signaling moiety for HAS2 transcription and increases the activity and 
stability of HAS2 (Vigetti et al. 2012). Thiamet G is shown to protect the O-GlcNAc 
modification by inhibiting the OGA in HAS2. So the question arises weather this O-GlcNAc 
influence HAS3 activity trafficking and HA synthesis. In our experiments it has not 
influenced the expression of HAS3. The above result in our study concludes that the 
availability UDP-substrates can directly effects the HAS3 traffic from Golgi to PM. 
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6.5 Endocytosis of HAS3 from plasmembrane   
There is not much known about HAS endocytosis and very few supporting data is available 
in the literature. Kultti et al has shown that cholesterol depletion can inhibit HA production, 
when cells are treated with methyl-β-cyclodextrin (MβCD). MβCD reduces HAS2 expression 
by inhibiting phosphoinositide 3-kinase-Akt pathway. This shows the novel role played by 
MβCD in inhibition of HA synthesis without altering the UDP-sugars. But the study did not 
explain whether MβCD dependent inhibition 3-kinase-Akt pathway can also affect the 
endocytosis HAS2 (Kultti et al. 2010). 
In a recently published study by Deen et al showed that Rab10 GTPases are involved in the 
endocytosis of HAS3 and Rab10 silencing has increased plasma membrane residence of 
HAS3  (Deen et al. 2014). Though the above study was related to HAS3 endocytosis, it did   
not focus on the trafficking of Dendra2-HAS3 from Golgi-PM and recycling of HAS3. 
In our project, first time a study was done on endocytosis of Dendra2-HAS3 in melanoma 
cells, treated with 4-MU and Mannose. As hypothesized the alteration of UDP-substrate 
sugars with 4-MU and Mannose has increased the HAS3 endocytosis. A more specific and 
functional pathway of endocytosis has to be investigated to inspect whether UDP-sugar 
alterations can also affect the recycling endocytosis, which in turn can influence the HA 
synthesis. 
6.6 Recycling Assay of HAS3   
Recycling is a common virtue of a protein stored in a vesicle, having the ability to rapidly 
mobilize a particular protein to its site of action upon extra-cellular stimulation. These 
recycling proteins are embedded in the recycling endosome that can move to different 
cellular locations up on need. In our project we tried to study the recycling of HAS3 protein 
and to investigate its influence on HA synthesis. 
Previously, people have studied recycling of proteins and target molecules by variety of 
approaches and methods. Manna et al have studied the endocytic recycling of potassium 
(KATP) channels by secondary antibody capture assay, i.e. initially the surface proteins were 
stained with fluorescently tagged antibody and then the cells were cooled on ice to allow for 
the second antibody with a different color to bind. And then, while allowing the cells to warm  
to retrieve endocytosis, the authors have identified the movement of different colored vesicles 
and thereby analyzed the recycling of both the vesicles, stained with different colors. Later 
the colocalization analysis was done by using Image J software (Manna et al. 2010). 
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Tranferrin (Tf) and Transferrin receptors (TfR) are glycoprotein’s present in wide variety of 
cells (Ponka and Lok 1999). Tf has been widely reported as a prototype maker to study the 
recycling pathways and endocytosis of many proteins (Dam et al. 2002). Darmar et al 
reported that TfR was used as a potential imaging marker for studying the human cancer. TfR 
has represented as suitable target for applying molecular imaging technologies which are 
used to detect of tumors (Högemann-Savellano D et al. 2003). Phosphatidylinositol 3-Kinases 
(PI 3-kinases) play a key role in controlling the membrane traffic. Dam et al has investigated 
the role of PI-3 kinases on Tf recycling by using Tf fluorescent probe. It was clear that PI-3 
kinases are required for Tf recycling (Dam et al. 2002). We have also used Tf marker to study 
the recycling of HAS3. 
Colocalization-based analysis method was used in our studies, as described in (Rappoport 
and Simon 2003) and to study the recycling of HAS3 in melanoma cells. Tf as a marker used 
to study the recycling of mRFP-HAS3. To analyze the colocalization spots a new imaging 
software called Bio-ImageXD was used, its an open access software devoted to 3D analysis 
of microscopy images  (Kankaanpää et al. 2012). 
HAS3 recycling assay in live cell imaging was done by using a different approach and 
analysis with the help of BioImageXD software. Using segmentation, an option used for 
identification of individual vesicles as a matter of voxel-related objects based on its size, 
intensity and distribution, we have labeled EGFP-HAS3 vesicles inside the cells. By using 
the function called motion tracking, the independent recycling tracks of EGFP-HAS3 vesicles 
can be analyzed and thereby sort out HAS3 recycling.   
In our experiment when cells transfected with mRPF-HAS3 and treated with the same 
reagents, only mannose has significantly reduced the recycling vesicles in all the time points. 
Whereas 4-MU and Thiamet G also influenced the recycling but the results were not 
consistent. In live cells when compared to control group, mannose treated cells showed 
significantly reduced number of recycling tracks of EGFP-HAS3 (Fig 16). This result 
supports our Dendra2-HAS3 endocytosis data where mannose has been more potent to in 
increasing the HAS3 endocytosis (Fig 12). The present findings also supports the literature 
that the cellular content of UDP-GlcNAc which is 3-7 times higher than UDP-GlcUA (N 
Itano et al. 1999b). 
It can be concluded from the above results that mannose has shown more potent effect than 4-
MU in both the trafficking experiments. However we have not studied the dose dependent 
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effect of these chemicals. The variations in the results could be because UDP substrates may 
have different properties at various levels. 
6.7 Influence of cell proliferation and migration on MV3-HAS3 cells 
Proliferation Assay 
HA plays a key role in proliferation in many cell types including tumor cells and HA supports 
cell proliferation, though the mechanism behind it is still unclear. The rate of cell 
proliferation is often associated with HA synthesis and previous studies have shown that 4-
MU inhibits cell proliferation in various cell lines (Saito 2012). In the same study 4-MU has 
inhibited the cell proliferation and induced apoptosis in mammary tumor cells. Mannose has 
also reduced cell proliferation in human dermal fibroblasts but not to a significant extent 
(Jokela et al. 2013a). Since our present study focuses on HAS3 it is been reported that HAS3 
suppression  resulted in decreased  cell proliferation and invasion (Tofuku et al. 2006). 
In the current study we have used MV3-HAS3 stably expressed cells treated with 4-MU, 
Mannose and Thiamet-G and fixed after 24, 48 and 72 hrs time point. 4-MU has slightly 
decreased the proliferation rate as this effect is dose dependent as per previously published 
studies (Kultti et al. 2006) , where as mannose has significantly decreased the proliferation in 
MV3 HAS3 cells and Thiamet-G did not influenced the proliferation. 
Migration Assay 
HA stimulates cell motility in several cell lines (Yoshinari et al. 1999), previous literature has 
shown that HAS2 suppression by antisense (Rilla et al. 2002) or by siRNA transfection (Li et 
al. 2007) has shown to decrease in cell migration. 4-MU has shown to decrease cell migration 
in keratinocytes (Rilla et al. 2004) and also inhibited HA synthesis. Mannose on the other 
hand inhibited dermal fibroblasts invasion and also suppressing the migration and HA 
dependent monocyte binding (Jokela et al. 2013b). 
In the present study we used the same cell line MV3-HAS3 and the cells were treated with 
the same agents. 4-MU has decreased the migration levels and Mannose has increased the 
migration levels and Thiamet-G did not influence the proliferation of MV3-HAS3 cells. This 
result supports the previously published studies where 4-MU has decreased the cell 
migration. Whereas Mannose has increased the cell migration, this could be because of to 
high suppression of HA synthesis but the increase is not significant and more studies have to 
be done to verify this, as very little literature is available on this. 
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Conclusions and views for the future 
Cellular trafficking has played pivotal role in controlling many important aspects of the cell. 
In our experiments, the availability of UDP-GlcUA and UDP-GlcNAc has influenced 
intracellular trafficking of HAS3 (i.e. Golgi-to-PM traffic, endocytosis and recycling 
endocytosis), which in turn has affected HA synthesis. 
Several other biological functions like proliferation and migration were also influenced by 
HA synthesis. It would be interesting to study whether HAS3 dependent HA can also 
influence other biological functions like cell adhesion and invasion. 
Over all, the study has opened a new window in exploring the traffic of proteins and how it 
can influence various cellular functions. It has discovered the key connection of HAS3 traffic 
empowering HA synthesis. The knowledge of protein trafficking can be applied in various 
biological fields in understanding many molecular aspects of many diseases. 
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7. CONCLUSIONS AND SUMMARY 
HA is an extracellular polysaccharide, which plays crucial role in cancer and inflammation. 
The present project is about studying the intra-cellular trafficking of HAS3 and its influence 
on HA synthesis. HASs use UDP-sugars to synthesize and secrete HA, and any alterations in 
the UDP sugars have direct influence on HA secretion. 
After 4-MU and mannose treatments the intracellular trafficking of Dendra2-HAS3 from 
Golgi-to-PM was significantly decreased. At the same time the endocytosis of Dendra2-
HAS3 was also significantly increased with the same treatment. This shows the direct relation 
between trafficking of HASs and UDP-sugar levels. 
In the recycling assay the various recycling paths of mRFP-HAS3 or EGFP-HAS3 in both 
fixed cells and live cells were studied. Transferrin marker and Bio-ImageXD are the 
techniques’ employed to analyze the colocalization spots and recycling tracks. Mannose 
significantly reduced the recycling of HAS3 in every time point. 
In all of the experiments mannose treatments resulted in consistent results; demonstrating the 
role of UDP-sugar N-acetlyglucosamine in HA biosynthesis pathway. Both mannose and     
4-MU significantly influenced the traffic of Dendra2-HAS3 from Golgi to PM and 
endocytosis, with mannose being more potent. 4-MU also affected the fast recycling assay of 
HAS3 but did not significantly influenced the HA secretion and other biological functions 
like proliferation and migration. Mannose and Thiamet G clearly showed the effect on 
recycling assay. Mannose slightly increased the migration assay, where as Thiamet G and 4-
MU did not show any effect. This shows that biological functions can vary between the 2 
UDP sugars UDP-GlcUA and UDP-GlcNAc. On the other hand the role of O-GlcNAc 
signaling, influenced by Thiamet G on HAS3 traffic and HA synthesis needs to be studied in 
detail in a more robustic and systematic manner. 
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Figure 19. Intracellular traffic of HAS3 is regulated by its substrate supply: (A) HAS3 vesicle 
transport from Golgi to PM, (B) HAS3 using UDP-sugars synthesize and secrete HA , (C) HAS3 
proteins undergoing endocytosis , (D) HAS3 fast recycling vesicles and (E) HAS3 slow recycling 
back to the PM 
 
 
 
 
 
 
1* -4-MU and Mannose increased endocytosis of HAS3 
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